Literature DB >> 2073105

Pharmacokinetics of cefprozil in infants and children.

X Sáez-Llorens1, W C Shyu, S Shelton, H Kumiesz, J Nelson.   

Abstract

Twenty pediatric patients (ages, between 8 months and 8 years) received a single oral dose of cefprozil at levels of 15 and 30 mg/kg of body weight. Cefprozil consists of cis (BMY-28100) and trans (BMY-28167) isomers in an approximately 90:10 ratio. Six plasma samples were collected from each pediatric patient and assayed for drug concentrations. As measured by a microbiological assay, peak concentrations of 11.16 and 15.93 micrograms of cefprozil per ml occurred at 1 h for patients who received the 15- and 30-mg/kg doses, respectively. The respective mean half-lives of cefprozil were 1.77 and 2.14 h, and the respective mean areas under the curve were 28.05 and 45.28 micrograms.h/ml for patients who received the 15- and 30-mg/kg doses. When measured by a high-pressure liquid chromatography method, peak concentrations of 12.09 and 18.04 micrograms of the cis isomer per ml were obtained at 1 h, with mean half-lives of 1.63 and 2.06 h and mean areas under the curve of 30.48 and 49.34 micrograms.h/ml in patients who received the 15- and 30-mg/kg doses, respectively. For the trans isomer, peak concentrations of 1.16 and 1.63 micrograms/ml occurred at 1 h, respectively, with mean half-lives of 1.61 and 1.65 h and mean areas under the curve of 2.89 and 4.34 micrograms.h/ml in patients who received the 15- and 30-mg/kg doses, respectively.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073105      PMCID: PMC172016          DOI: 10.1128/AAC.34.11.2152

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Phase I study of multiple-dose cefprozil and comparison with cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Phase I study of single-dose BMY-28100, a new oral cephalosporin.

Authors:  R H Barbhaiya; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

3.  Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

Authors:  S Riegelman; P Collier
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

5.  BMY 28100, a new oral cephalosporin.

Authors:  F Leitner; T A Pursiano; R E Buck; Y H Tsai; D R Chisholm; M Misiek; J V Desiderio; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

  5 in total
  3 in total

1.  Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.

Authors:  D P Nicolau; C O Onyeji; M Zhong; P R Tessier; M A Banevicius; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 2.  Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.

Authors:  L R Wiseman; P Benfield
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 3.  Comparative microbiological activity and pharmacokinetics of cefprozil.

Authors:  R Wise
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-10       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.